Mutual of America Capital Management LLC Makes New Investment in Sotera Health (NYSE:SHC)

Mutual of America Capital Management LLC purchased a new position in Sotera Health (NYSE:SHCGet Rating) in the 2nd quarter, HoldingsChannel.com reports. The firm purchased 82,752 shares of the company’s stock, valued at approximately $1,621,000.

Several other institutional investors also recently modified their holdings of SHC. MetLife Investment Management LLC bought a new position in shares of Sotera Health in the 1st quarter worth about $139,000. Federated Hermes Inc. bought a new position in shares of Sotera Health in the 1st quarter worth about $157,000. Securian Asset Management Inc. bought a new position in shares of Sotera Health in the 2nd quarter worth about $177,000. Profund Advisors LLC increased its stake in shares of Sotera Health by 20.0% in the 2nd quarter. Profund Advisors LLC now owns 14,799 shares of the company’s stock worth $290,000 after acquiring an additional 2,463 shares in the last quarter. Finally, Handelsbanken Fonder AB bought a new position in shares of Sotera Health in the 2nd quarter worth about $294,000. 88.38% of the stock is currently owned by institutional investors.

Sotera Health Stock Performance

Shares of NYSE SHC opened at $8.25 on Friday. The firm’s 50-day moving average price is $7.32 and its 200-day moving average price is $15.14. The company has a quick ratio of 2.74, a current ratio of 3.00 and a debt-to-equity ratio of 2.97. The company has a market cap of $2.33 billion, a PE ratio of 18.75 and a beta of 1.27. Sotera Health has a 52-week low of $5.78 and a 52-week high of $24.90.

Wall Street Analyst Weigh In

A number of research firms have weighed in on SHC. JPMorgan Chase & Co. reduced their price objective on shares of Sotera Health from $9.00 to $6.00 and set an “underweight” rating for the company in a research note on Thursday, November 3rd. The Goldman Sachs Group reduced their price objective on shares of Sotera Health from $9.00 to $8.00 and set a “neutral” rating for the company in a research note on Wednesday. Barclays lowered shares of Sotera Health from an “equal weight” rating to an “underweight” rating and reduced their price objective for the company from $7.00 to $6.00 in a research note on Tuesday, November 15th. Royal Bank of Canada reduced their price objective on shares of Sotera Health from $25.00 to $8.00 and set an “outperform” rating for the company in a research note on Thursday, November 3rd. Finally, Citigroup lowered shares of Sotera Health from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $25.00 to $9.00 in a research note on Wednesday, October 5th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $15.89.

Sotera Health Company Profile

(Get Rating)

Sotera Health Company provides sterilization, and lab testing and advisory services in the United States, Canada, Europe, and internationally. The company's sterilization services include gamma and electron beam irradiation, and EO processing; Nelson Labs comprise microbiological and analytical chemistry testing; and advisory services for medical device and biopharmaceutical industries.

Read More

Want to see what other hedge funds are holding SHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sotera Health (NYSE:SHCGet Rating).

Institutional Ownership by Quarter for Sotera Health (NYSE:SHC)

Receive News & Ratings for Sotera Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sotera Health and related companies with MarketBeat.com's FREE daily email newsletter.